Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cboe UK EUR

Euroapi S.A. (EAPIP.XC)

2.7940
0.0000
(0.00%)
At close: December 24 at 10:42:03 AM GMT
Loading Chart for EAPIP.XC
  • Previous Close 2.7940
  • Open 2.7940
  • Bid 2.9860 x --
  • Ask 3.1000 x --
  • Day's Range 2.7940 - 2.7940
  • 52 Week Range 2.3340 - 3.8760
  • Volume 330
  • Avg. Volume 0
  • Market Cap (intraday) 266.068M
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3800
  • Earnings Date Jul 29, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances, as well as lipids. It offers their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company was incorporated in 2020 and is based in Paris, France.

www.euroapi.com/en

3,187

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EAPIP.XC

View More

Performance Overview: EAPIP.XC

Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

EAPIP.XC
0.00%
CAC 40 (^FCHI)
5.28%

1-Year Return

EAPIP.XC
19.71%
CAC 40 (^FCHI)
1.82%

3-Year Return

EAPIP.XC
81.11%
CAC 40 (^FCHI)
20.93%

5-Year Return

EAPIP.XC
81.11%
CAC 40 (^FCHI)
69.95%

Compare To: EAPIP.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EAPIP.XC

View More

Valuation Measures

Annual
As of 3/21/2025
  • Market Cap

    264.73M

  • Enterprise Value

    254.73M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.29

  • Price/Book (mrq)

    0.27

  • Enterprise Value/Revenue

    0.28

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -14.21%

  • Return on Assets (ttm)

    -0.53%

  • Return on Equity (ttm)

    -13.67%

  • Revenue (ttm)

    919.2M

  • Net Income Avi to Common (ttm)

    -130.6M

  • Diluted EPS (ttm)

    -1.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    73M

  • Total Debt/Equity (mrq)

    7.03%

  • Levered Free Cash Flow (ttm)

    121.21M

Research Analysis: EAPIP.XC

View More

Company Insights: EAPIP.XC

Research Reports: EAPIP.XC

View More